Stem Cell Therapeutics Announces Traumatic Brain Injury Presentation at the Advanced Technology Applications for Combat Casualty Care 2009 Conference

CALGARY, ALBERTA--(Marketwire - August 04, 2009) - Stem Cell Therapeutics Corp. (“SCT” or the “Company”) (TSX VENTURE: SSS) is pleased to announce Dr. Alan Moore, President and CEO, will be presenting at the Advanced Technology Applications for Combat Casualty Care (“ATACCC”) 2009 conference being held August 10-12 in St. Pete Beach, Florida. Dr. Moore will be discussing patient recovery from brain injury by pharmacological (‘drug-induced’) activation of endogenous neural adult stem cells in traumatic brain injury (“TBI”) and stroke. This discussion of recovery will be supported by SCT’s Phase IIa and Phase IIb clinical data in acute ischemic stroke patients and SCT’s preclinical data from animal models of TBI.

Dr. Alan Moore, President and CEO, commented as follows:

“We have been searching for a suitable venue to acquaint the arned services with our pre-clinical and clinical work. We are especially pleased to have the opportunity to present our regimens for the treatment of traumatic brain injury and stroke at such an important meeting.”

About ATACCC (https://www.usaccc.org/ATACCC/): The ATACCC is the U.S. Department of Defense’s (“DOD”) premier scientific meeting that addresses critical advances in trauma medicine and the unique medical needs of the war-fighter. It will focus on growing and changing operational issues and the technologies available today and in the future that can be used to meet these increasingly complex goals. Nearly all of DOD’s combat casualty care scientists will present their latest research results.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The Company’s programs aim to repair brain and nerve function lost due to disease or injury. The Company’s extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quaarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.